Literature DB >> 15278580

Pharmacokinetics and pharmacodynamics of vecuronium bromide.

T Nomura1.   

Abstract

The pharmacokinetics and pharmacodynamics of vecuronium bromide were studied in patients under general anesthesia of enflurane and nitrous oxide in oxygen. Eighteen patients were randomly divided into two groups which received either 0.05 mg.kg(-1) (low dose group) or 0.20 mg.kg(-1) (high dose group) of vecuronium intravenously. The plasma concentration of vecuronium was determined by high performance liquid chromatography. The neuromuscular blocking effect was assessed by measuring the twitch tension of the adductor pollicis muscle elicited by supramaximal electrical stimulation. Pharmacokinetic analysis was carried out using a two compartment model. The relationship between the T4/T1 and T1/ control T1 ratios differed during onset and spontaneous offset of the blockade; the T4/T1 ratios were significantly higher during onset than during offset, although there were large variations of fade in the train-of-four response in each patient during offset. These results suggest that it is difficult to estimate the T1/control T1 ratio by the T4/T1 ratio during offset. Pharmacokinetic analysis revealed that the high dose group had a shorter elimination half-life than did the low dose group. A shorter elimination half-life at a high dose may be to some extent due to hepatic clearance. The pharmacokinetic parameters bore no fixed relationship to the pharmacodynamics in each patient.

Entities:  

Year:  1992        PMID: 15278580     DOI: 10.1007/s0054020060028

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  25 in total

1.  Pharmacokinetics of pancuronium in patients with normal and impaired renal function.

Authors:  K McLeod; M J Watson; M D Rawlins
Journal:  Br J Anaesth       Date:  1976-04       Impact factor: 9.166

2.  The emergence of ORG NC 45, 1- [2 beta,3 alpha,5 alpha,16 beta,17 beta)-3, 17-bis(acetyloxy)-2-(1-piperidinyl)-androstan-16-yl]-1-methylpiperidinium bromide, from the pancuronium series.

Authors:  D S Savage; T Sleigh; I Carlyle
Journal:  Br J Anaesth       Date:  1980       Impact factor: 9.166

3.  [Pharmacokinetics and pharmacodynamics of vecuronium and pancuronium in anesthetized man].

Authors:  C Yajima; N Sugai; Y Inada
Journal:  Masui       Date:  1985-09

Review 4.  Prejunctional and postjunctional cholinoceptors at the neuromuscular junction.

Authors:  W C Bowman
Journal:  Anesth Analg       Date:  1980-12       Impact factor: 5.108

5.  Disposition of vecuronium bromide in the cat.

Authors:  A F Bencini; A H Scaf; S Agoston; M C Houwertjes; U W Kersten
Journal:  Br J Anaesth       Date:  1985-08       Impact factor: 9.166

6.  Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure.

Authors:  A F Bencini; A H Scaf; Y J Sohn; C Meistelman; A Lienhart; U W Kersten; S Schwarz; S Agoston
Journal:  Anesth Analg       Date:  1986-03       Impact factor: 5.108

7.  Pharmacokinetics of Org NC45 (norcuron) in patients with and without renal failure.

Authors:  M R Fahey; R B Morris; R D Miller; T L Nguyen; R A Upton
Journal:  Br J Anaesth       Date:  1981-10       Impact factor: 9.166

8.  Pharmacokinetics and pharmacodynamics of Org NC 45 in man.

Authors:  F van der Veen; A Bencini
Journal:  Br J Anaesth       Date:  1980       Impact factor: 9.166

9.  Determination of Org NC 45 (a myoneural blocking agent) in human plasma using high-performance normal-phase liquid chromatography.

Authors:  J E Paanakker; G L van de Laar
Journal:  J Chromatogr       Date:  1980-10-10

10.  Twitch, tetanus and train-of-four as indices of recovery from nondepolarizing neuromuscular blockade.

Authors:  H H Ali; J J Savarese; P W Lebowitz; F M Ramsey
Journal:  Anesthesiology       Date:  1981-04       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.